Preclinical Studies on Intestinal Administration of Antisense Oligonucleotides as a Model for Oral Delivery for Treatment of Duchenne Muscular Dystrophy

Antisense oligonucleotides (AONs) used to reframe dystrophin mRNA transcripts for Duchenne muscular dystrophy (DMD) patients are tested in clinical trials. Here, AONs are administered subcutaneously and intravenously, while the less invasive oral route would be preferred. Oral delivery of encapsulat...

Descrición completa

Detalles Bibliográficos

Principais autores:	Maaike van Putten, Courtney Young, Sjoerd van den Berg, Amanda Pronk, Margriet Hulsker, Tatyana G Karnaoukh, Rick Vermue, Ko Willems van Dijk, Sjef de Kimpe, Annemieke Aartsma-Rus
Formato:	Artigo
Idioma:	Inglês
Publicado:	Elsevier 2014-01-01
Series:	Molecular Therapy: Nucleic Acids
Assuntos:	antisense oligonucleotides bioavailability Duchenne muscular dystrophy dystrophin oral administration
Acceso en liña:	http://www.sciencedirect.com/science/article/pii/S216225311630350X
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!